| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Investigations |
Departments of Pathology [M. L., C. R. A., J. M. W.], Epidemiology and Biostatistics [D. H. L.], and Surgery [A. K., J. H. H., M. F. B.], Memorial Sloan-Kettering Cancer Center, New York, New York 10021; Departments of Pathology [J. A. B.], Pediatrics [J. A. B.], and Orthopaedic Surgery [J. A. B., J. R. N.], University of Nebraska Medical Center, Omaha, Nebraska, 68198; Department of Pathology [F. G. B., J. D. G.], University of Pennsylvania Medical Center, Philadelphia, Pennsylvania; Department of Pathology, Roswell Park Cancer Institute, Buffalo, New York 14263 [J. S. J. B.]; Department of Pathology, Cleveland Clinic Foundation, Cleveland, Ohio 44195 [J. R. G.]; Department of Pathology, The Johns Hopkins Hospital, Baltimore, Maryland 21287 [S. Z. A.]; Institute for Cancer Research [J. S., C. S. C.] and Department of Pathology [C. F.], The Royal Marsden NHS Trust, London and Sutton, Surrey, United Kingdom SM2 5NG; Department of Orthopaedics, Stockholm Söder Hospital, SE-100 64, Stockholm, Sweden [B. S.]; and Cellular and Molecular Tumor Pathology, Karolinska Hospital, SE-171 76 Stockholm, Sweden [O. L.]
Synovial sarcomas are aggressive spindle cell sarcomas containing in some cases areas of epithelial differentiation. They consistently show a specific t(X;18;p11;q11), which usually represents either of two gene fusions, SYT-SSX1 or SYT-SSX2, encoding putative transcriptional proteins differing at 13 amino acid positions. Previous studies have suggested that patients with SYT-SSX2 tumors do better than those with SYT-SSX1 tumors, but the study groups were too limited to be conclusive. To address this issue more definitively, we collected data on SYT-SSX fusion type, pathology, and clinical course in a retrospective multi-institutional study of 243 patients (age range, 6–82) with synovial sarcoma. SYT-SSX1 and SYT-SSX2 fusions were detected in 147 tumors (61%) and 91 tumors (37%), respectively. Histologically, 61 (25%) were classified as biphasic type and 180 (74%) as monophasic type based on the presence or absence of areas of glandular epithelial differentiation, respectively. Median and 5-year overall survivals for the SYT-SSX1 and SYT-SSX2 groups were 6.1 years and 53%, and 13.7 years and 73%, respectively. Overall survival was significantly better among SYT-SSX2 cases (P = 0.03), among cases localized at diagnosis (P < 0.0001), and among patients with primary tumors < 5 cm in greatest dimension (P = 0.01). Age, sex, histological type, and axial versus peripheral primary site had no impact on overall survival. The impact of fusion type on survival remained significant when stratified for primary tumor size (P = 0.03) but was no longer significant when stratified for disease status at presentation. This may reflect the tendency for patients with SYT-SSX1 tumors to present more often with metastatic disease (P = 0.05). Cox regression identified disease status (P < 0.0001) and primary tumor size (P = 0.04) as the only factors independently predictive of overall survival in the subset of 160 patients with information on all of the factors. Within the subset of patients with localized disease at diagnosis (n = 202), the median and 5-year survival for the SYT-SSX1 and the SYT-SSX2 groups were 9.2 years and 61% versus 13.7 years and 77%, respectively. Patients whose tumors contained the SYT-SSX2 fusion (P = 0.08) or were smaller (P = 0.12) showed a trend toward better survival by log-rank test, whereas tumor histology had no impact (P = 0.8). In a Cox regression analysis considering all of the factors, SYT-SSX fusion type emerged as the only independent significant factor (P = 0.04) for overall survival within the subset of 133 patients with localized disease at diagnosis who had information on all of the factors. Among other comparisons, there was a strong association of fusion type and morphology (P < 0.001), with almost all of the SYT-SSX2 tumors showing absence of glandular differentiation (monophasic histology) and almost all of the biphasic tumors containing SYT-SSX1. There was also a statistically significant association of fusion type and patient sex (P = 0.03); specifically, the male:female ratio of SYT-SSX1 cases was 1:1, whereas for SYT-SSX2 cases, it was close to 1:2. Overall, SYT-SSX fusion type appears to be the single most significant prognostic factor by multivariate analysis in patients with localized disease at diagnosis. SYT-SSX fusion type also appears to exert part of its impact on prognosis before presentation through its association with stage at diagnosis. In addition, the associations of SYT-SSX fusion type with patient sex and tumor epithelial differentiation point to interesting mechanistic biological differences.
This article has been cited by other articles:
|
|
 |
|
  M. S. Merchant and C. L. Mackall Current Approach to Pediatric Soft Tissue Sarcomas Oncologist, November 1, 2009; 14(11): 1139 - 1153. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Italiano, N. Penel, Y.-M. Robin, B. Bui, A. Le Cesne, S. Piperno-Neumann, M. Tubiana-Hulin, E. Bompas, C. Chevreau, N. Isambert, et al. Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group Ann. Onc., March 1, 2009; 20(3): 425 - 430. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Canter, L.-X. Qin, R. G. Maki, M. F. Brennan, M. Ladanyi, and S. Singer A Synovial Sarcoma-Specific Preoperative Nomogram Supports a Survival Benefit to Ifosfamide-Based Chemotherapy and Improves Risk Stratification for Patients Clin. Cancer Res., December 15, 2008; 14(24): 8191 - 8197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Slater and J. Shipley Clinical relevance of molecular genetics to paediatric sarcomas J. Clin. Pathol., November 1, 2007; 60(11): 1187 - 1194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Palau L, T. Thu Pham, N. Barnard, and M. J. Merino Primary Synovial Sarcoma of the Kidney With Rhabdoid Features International Journal of Surgical Pathology, October 1, 2007; 15(4): 421 - 428. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Ishida, M. Miyamoto, S. Naitoh, D. Tatsuda, T. Hasegawa, T. Nemoto, H. Yokozeki, K. Nishioka, A. Matsukage, M. Ohki, et al. The SYT-SSX Fusion Protein Down-Regulates the Cell Proliferation Regulator COM1 in t(x;18) Synovial Sarcoma Mol. Cell. Biol., February 15, 2007; 27(4): 1348 - 1355. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R.H. de Bruijn, S. V. Allander, A. H.A. van Dijk, M. P. Willemse, J. Thijssen, J. J.M. van Groningen, P. S. Meltzer, and A. Geurts van Kessel The Synovial Sarcoma-Associated SS18-SSX2 Fusion Protein Induces Epigenetic Gene (De)Regulation Cancer Res., October 1, 2006; 66(19): 9474 - 9482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D.R.H. de Bruijn, W.J.M. Peters, S.M. Chuva de Sousa Lopes, A.H.A. van Dijk, M.P. Willemse, R. Pfundt, P. de Boer, and A. Geurts van Kessel Targeted disruption of the synovial sarcoma-associated SS18 gene causes early embryonic lethality and affects PPARBP expression Hum. Mol. Genet., October 1, 2006; 15(19): 2936 - 2944. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Saito, M. Nagai, and M. Ladanyi SYT-SSX1 and SYT-SSX2 Interfere with Repression of E-Cadherin by Snail and Slug: A Potential Mechanism for Aberrant Mesenchymal to Epithelial Transition in Human Synovial Sarcoma. Cancer Res., July 15, 2006; 66(14): 6919 - 6927. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Watanabe, M. Tsuda, Y. Makino, S. Ichihara, H. Sawa, A. Minami, N. Mochizuki, K. Nagashima, and S. Tanaka Adaptor Molecule Crk Is Required for Sustained Phosphorylation of Grb2-Associated Binder 1 and Hepatocyte Growth Factor-Induced Cell Motility of Human Synovial Sarcoma Cell Lines Mol. Cancer Res., July 1, 2006; 4(7): 499 - 510. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Granowetter Pediatric Oncology Integr Cancer Ther, March 1, 2006; 5(1): 49 - 50. [PDF]
|
|
|
|
 |
|
 M. A. Clark, C. Fisher, I. Judson, and J. M. Thomas Soft-Tissue Sarcomas in Adults N. Engl. J. Med., August 18, 2005; 353(7): 701 - 711. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ladanyi Correlates of SYT-SSX Fusion Type in Synovial Sarcoma: Getting More Complex But Also More Interesting? J. Clin. Oncol., May 20, 2005; 23(15): 3638 - 3639. [Full Text] [PDF]
|
|
|
|
|
|
L. Guillou and J.-M. Coindre In Reply: J. Clin. Oncol., May 20, 2005; 23(15): 3639 - 3640. [Full Text] [PDF]
|
|
|
|
|
|
A. M. Oliveira and C. D.M. Fletcher Molecular Prognostication for Soft Tissue Sarcomas: Are We Ready Yet? J. Clin. Oncol., October 15, 2004; 22(20): 4031 - 4034. [Full Text] [PDF]
|
|
|
|
|
|
L. Guillou, J. Benhattar, F. Bonichon, G. Gallagher, P. Terrier, E. Stauffer, N. de Saint Aubain Somerhausen, J.-J. Michels, G. Jundt, D. R. Vince, et al. Histologic Grade, But Not SYT-SSX Fusion Type, Is an Important Prognostic Factor in Patients With Synovial Sarcoma: A Multicenter, Retrospective Analysis J. Clin. Oncol., October 15, 2004; 22(20): 4040 - 4050. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ottaiano, A. De Chiara, F. Perrone, G. Botti, F. Fazioli, V. De Rosa, N. Mozzillo, V. Ravo, B. Morrica, C. Gallo, et al. Prognostic Value of CD40 in Adult Soft Tissue Sarcomas Clin. Cancer Res., April 15, 2004; 10(8): 2824 - 2831. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-C. Chang and V. B. Shidham Molecular Genetics of Pediatric Soft Tissue Tumors: Clinical Application J. Mol. Diagn., August 1, 2003; 5(3): 143 - 154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Weitz, C. R. Antonescu, and M. F. Brennan Localized Extremity Soft Tissue Sarcoma: Improved Knowledge With Unchanged Survival Over Time J. Clin. Oncol., July 15, 2003; 21(14): 2719 - 2725. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. C. Borden, L. H. Baker, R. S. Bell, V. Bramwell, G. D. Demetri, B. L. Eisenberg, C. D. M. Fletcher, J. A. Fletcher, M. Ladanyi, P. Meltzer, et al. Soft Tissue Sarcomas of Adults: State of the Translational Science Clin. Cancer Res., June 1, 2003; 9(6): 1941 - 1956. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. Okcu, M. Munsell, J. Treuner, A. Mattke, A. Pappo, A. Cain, A. Ferrari, M. Casanova, A. Ozkan, and B. Raney Synovial Sarcoma of Childhood and Adolescence: A Multicenter, Multivariate Analysis of Outcome J. Clin. Oncol., April 15, 2003; 21(8): 1602 - 1611. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. V. Allander, P. B. Illei, Y. Chen, C. R. Antonescu, M. Bittner, M. Ladanyi, and P. S. Meltzer Expression Profiling of Synovial Sarcoma by cDNA Microarrays : Association of ERBB2, IGFBP2, and ELF3 with Epithelial Differentiation Am. J. Pathol., November 1, 2002; 161(5): 1587 - 1595. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. O'Sullivan, P. A. Humphrey, L. P. Dehner, and J. D. Pfeifer t(X;18) Reverse Transcriptase-Polymerase Chain Reaction Demonstrating a Variant Transcript J. Mol. Diagn., August 1, 2002; 4(3): 178 - 180. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
